Outliers in study intended for RSABE [Study As­sess­ment]

posted by Ohlbe – France, 2021-04-26 20:30 (651 d 11:21 ago) – Posting: # 22325
Views: 1,901

Dear Helmut,

❝ ❝ Subject A - had BLQ (Below limit of Quantification) for all the time points for one of Test treatment and

❝ ❝ Subject B - had BLQ for all the time points in one of Reference treatment.

❝ ❝

❝ ❝ Can we include Subject A & B for statistical analysis


❝ Well, the statistical model is based on \(\small{\log_{e}}\)-transformed data. You have to exclude them, since \(\small{\log_{e}(0)}\) is undefined (for nitpickers: \(\small{\lim \log_{e}(x\rightarrow 0) = -\infty}\)).


Well, indeed you can't analyse the study without excluding at least that period. NK's study is intended for the US FDA, I don't know how these guys react to such exclusions. In Europe, subject B could be excluded according to the EU BE guideline, but subject A could not as the period with all BLQ was after the test product. EU regulators will tell you that this might be due to your product and you can't exclude the data just because they don't suit you. In such a situation: you're screwed.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
19 visitors (0 registered, 19 guests [including 8 identified bots]).
Forum time: 06:51 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5